HLA-L and cancer: Of these, SECISBP2L (OR = 0.80, p = 5.2 × 10−8), HLA-L (OR = 0.84, p = 1.6 × 10−6), and DISP2 (OR = 1.25, p = 1.6 × 10−4) displayed consistent directions of effect for pulmonary function and lung cancer risk, whereby alleles associated with increased expression were associated with impaired FEV1 or FEV1/FVC and increased cancer risk (or conversely, positively associated with pulmonary function and inversely associated with cancer risk).